Eli Lilly is a well-established pharmaceutical company with a portfolio of products that consistently generate revenue and ...
In December 2025, J.P. Morgan upgraded Recursion Pharmaceuticals after REC-4881 showed rapid, durable polyp burden reductions and a favorable safety profile in familial adenomatous polyposis patients, ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) ranks among the best AI stocks to buy according to analysts. On December 17, ...
On December 17, 2025, JPMorgan raised Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) from Neutral to Overweight, with a price ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
Carrillo’s promotion reflects Menlo Ventures’ commitment to strengthening its leadership bench and supporting the firm’s long ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...
3don MSNOpinion
Wall Street's most shorted stocks at the start of 2026
The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...
ForGrowth III filed an initial 13D regarding its stake in the clinical-stage cell therapy company, shifting to the stance of ...
The year 2025 marked a major leap for AI in health care, with breakthroughs in drug discovery, diagnostics, genomics and ...
Wednesday’s market has seen notable movements in various stocks due to news and other factors. Today, stocks like Avago... Wednesday’s market has seen swings in various stocks based on news and other ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback